• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Angiogenesis-Regulating microRNAs and Ischemic Stroke.
Abstract Stroke is a leading cause of death and disability worldwide. Ischemic stroke is the dominant subtype of stroke and results from focal cerebral ischemia due to occlusion of major cerebral arteries. Thus, the restoration or improvement of reduced regional cerebral blood supply in a timely manner is very critical for improving stroke outcomes and post-stroke functional recovery. The recovery from ischemic stroke largely relies on appropriate restoration of blood flow via angiogenesis. Newly formed vessels would allow increased cerebral blood flow, thus increasing the amount of oxygen and nutrients delivered ...
Source: Current Vascular Pharmacology - May 13, 2013 Category: Drugs & Pharmacology Authors: Yin KJ, Hamblin M, Chen YE Tags: Curr Vasc Pharmacol Source Type: research

Angiogenesis-regulating microRNAs and Ischemic Stroke.
Abstract Stroke is a leading cause of death and disability worldwide. Ischemic stroke is the dominant subtype of stroke and results from focal cerebral ischemia due to occlusion of major cerebral arteries. Thus, the restoration or improvement of reduced regional cerebral blood supply in a timely manner is very critical for improving stroke outcomes and poststroke functional recovery. The recovery from ischemic stroke largely relies on appropriate restoration of blood flow via angiogenesis. Newly formed vessels would allow increased cerebral blood flow, thus increasing the amount of oxygen and nutrients delivered t...
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Yin KJ, Hamblin M, Chen YE Tags: Curr Vasc Pharmacol Source Type: research

Caveolin-1 in stroke neuropathology and neuroprotection: a novel molecular therapeutic target for ischemic-related injury.
Abstract Cardiovascular disease and associated cerebral stroke are a global epidemic attributed to genetic and epigenetic factors, such as diet, life style and an increasingly sedentary existence due to technological advances in both the developing and developed world. There are approximately 5.9 million stroke-related deaths worldwide annually. Current epidemiological data indicate that nearly 16.9 million people worldwide suffer a new or recurrent stroke yearly. In 2014 alone, 2.4% of adults in the United States (U.S.) were estimated to experience stroke, which is the leading cause of adult disability and the fi...
Source: Current Vascular Pharmacology - February 5, 2018 Category: Drugs & Pharmacology Authors: Wang S, Head BP Tags: Curr Vasc Pharmacol Source Type: research

Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies.
Abstract Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of...
Source: Current Vascular Pharmacology - January 1, 2014 Category: Drugs & Pharmacology Authors: Tuttolomondo A, Pecoraro R, Di Raimondo D, Arnao V, Clemente G, Corte VD, Maida C, Simonetta I, Licata G, Pinto A Tags: Curr Vasc Pharmacol Source Type: research

Acute antithrombotic treatment of ischemic stroke.
Abstract Antithrombotic medication is a cornerstone of acute ischemic stroke treatment and secondary prevention. The efficacy of thrombolysis with alteplase in acute stroke has been demonstrated in several clinical trials. This safe and costeffective therapy has transformed the practice of stroke care and has led to subsequent trials of other antithrombotic medications for treatment of ischemic stroke in the acute phase. These antithrombotics include thrombolytic, antiplatelet and anticoagulant agents. While, no other medication has yet demonstrated adequate efficacy, our current and evolving understanding of infa...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Alderazi YJ, Grotta JC Tags: Curr Vasc Pharmacol Source Type: research

Antiplatelets in stroke prevention.
Abstract Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both fo...
Source: Current Vascular Pharmacology - January 1, 2014 Category: Drugs & Pharmacology Authors: Pinto A, Di Raimondo D, Tuttolomondo A, Butta C, Licata G Tags: Curr Vasc Pharmacol Source Type: research

Stroke and Hypertension: an Appraisal from Pathophysiology to Clinical Practice.
Abstract Stroke as a cause of long-term disability is a growing public health burden. Therefore, focusing on prevention is important. The most prominent aim of this strategy is to treat modifiable risk factors, such as arterial hypertension, the leading modifiable contributor to stroke. Thus, efforts to adequately reduce blood pressure (BP) among hypertensives are mandatory. In this respect, although safety and benefits of BP control related to long-term outcome have been largely demonstrated, there are open questions that remain to be addressed, such as optimal timing to initiate BP reduction and BP goals to be t...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Buonacera A, Stancanelli B, Malatino L Tags: Curr Vasc Pharmacol Source Type: research

The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.
CONCLUSION: Based on the reviewed literature, allopurinol appears to be a promising therapy to improve vascular function and reduce disability in patients who have had a stroke. The benefits seen are in combination with current standard of care treatments with aspirin and lipid-lowering therapy. Larger trials are necessary to better understand the role of allopurinol in patients with history of stroke. PMID: 28933307 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - September 19, 2017 Category: Drugs & Pharmacology Authors: Britnell SR, Chillari KA, Brown JN Tags: Curr Vasc Pharmacol Source Type: research

Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
Curr Vasc Pharmacol. 2022;20(4):333-340. doi: 10.2174/1570161120666220428101337.ABSTRACTThe neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general populat...
Source: Current Vascular Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Authors: Alan King Karen M Doyle Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10